Shares of Personalis, Inc. (NASDAQ:PSNL – Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $13.91, but opened at $15.22. Personalis shares last traded at $15.0180, with a volume of 1,726,099 shares traded.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on PSNL shares. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. TD Cowen reiterated a “buy” rating on shares of Personalis in a research report on Wednesday, July 15th. BTIG Research boosted their price target on Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a report on Monday, July 20th. Zacks Research lowered Personalis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Finally, Needham & Company LLC downgraded shares of Personalis from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $14.25.
Read Our Latest Report on PSNL
Personalis Trading Up 11.4%
Personalis (NASDAQ:PSNL – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). The firm had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. On average, equities research analysts predict that Personalis, Inc. will post -1.07 earnings per share for the current fiscal year.
Insider Buying and Selling at Personalis
In other news, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00. Following the sale, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,783,662. This represents a 2.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 435,032 shares of company stock worth $5,599,929 in the last ninety days. 4.20% of the stock is owned by company insiders.
Hedge Funds Weigh In On Personalis
Several large investors have recently bought and sold shares of PSNL. Merck & Co. Inc. acquired a new position in shares of Personalis during the second quarter valued at approximately $188,202,236,000. T. Rowe Price Investment Management Inc. boosted its stake in Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after buying an additional 7,896,714 shares in the last quarter. BlackRock Inc. acquired a new position in Personalis during the second quarter worth about $94,905,000. Kennedy Capital Management LLC grew its holdings in Personalis by 196.2% during the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after acquiring an additional 1,281,695 shares during the period. Finally, Bank of America Corp DE bought a new stake in Personalis in the second quarter worth about $24,395,000. Institutional investors and hedge funds own 61.91% of the company’s stock.
Personalis Company Profile
Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.
In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.
Featured Articles
- Five stocks we like better than Personalis
- Datavault AI Locks Down CyberCatch in $94M Security Rollup
- Quantum Stocks Are Starting to Choose Sides: Should Investors Do the Same?
- AeroVironment Hit a Bottom in Q2—Can It Take Flight in Q3?
- The Pre-IPO Playbook: How to Cash in on Anthropic Before the Bell
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.
